ArticleEpidemics2017
Measuring and modelling the effects of systematic non-adherence to mass drug administration.
Article in Epidemics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Elimination of transmission of onchocerciasis (river blindness) with long-term ivermectin mass drug administration with or without vector control in sub-Saharan Africa: a systematic review and meta-analysis.The Lancet. Global health · 2024Pooled it
- Individual longitudinal compliance to neglected tropical disease mass drug administration programmes, a systematic review.PLoS neglected tropical diseases · 2023Pooled it
- Factors affecting the uptake of preventive chemotherapy treatment for schistosomiasis in Sub-Saharan Africa: A systematic review.PLoS neglected tropical diseases · 2021Pooled it
- Current epidemiological evidence for predisposition to high or low intensity human helminth infection: a systematic review.Parasites & vectors · 2018Pooled it
- How important is the spatial movement of people in attempts to eliminate the transmission of human helminth infections by mass drug administration?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023Trial
- Individual adherence to mass drug administration in neglected tropical disease control: A probability model conditional on past behaviour.PLoS neglected tropical diseases · 2021Trial
- Beneficiary feedback mechanisms: Exploring ways to systematically integrate community feedback in mass drug administration delivery for NTDs.PLoS neglected tropical diseases · 2026Article
- Article
- Modelling of onchocerciasis-associated skin and ocular disease and the impact of ivermectin treatment.Communications medicine · 2026Article
- HISTONCHO: A dataset of intervention histories for onchocerciasis control & elimination in sub-Saharan Africa.Scientific data · 2026Article
- Significant gap between Point participation and long‑term treatment adherence: An evaluation of ivermectin MDA in the Kwanware‑Ottou persistent onchocerciasis transmission focus, Wenchi, Ghana.PLoS neglected tropical diseases · 2026Article
- Exploring the landscape of lymphatic filariasis research in India: A scientometric analysis of two decades from 2000 to 2024.PLoS neglected tropical diseases · 2026Article
- High Levels of Community Support for Mansonellosis Interventions in an Endemic Area of the Brazilian Amazon.Tropical medicine and infectious disease · 2025Article
- Population-level impact of mass drug administration against schistosomiasis with anthelmintic drugs targeting juvenile schistosomes: a modelling study.The Lancet. Microbe · 2025Article
- How improvements to drug effectiveness impact mass drug administration for control and elimination of schistosomiasis.PLoS neglected tropical diseases · 2025Article
- Mass drug administration coverage and its determinants for the elimination of onchocerciasis in Ulanga District, Tanzania.PLoS neglected tropical diseases · 2025Article
- Model-Based Geostatistical Mapping of the Prevalence of Onchocerca volvulus in Cameroon between 1971 and 2020.PLoS neglected tropical diseases · 2025Article
- National Consensus on Introducing and Delivery of Paediatric Praziquantel for Curative and Preventive Treatment of Schistosomiasis Among Pre-school Children in Tanzania.The East African health research journal · 2025Article
- Integrating social and behavior change communication into mass drug administration campaigns for neglected tropical diseases: insights and best practices from Jimma, Ethiopia.Frontiers in public health · 2025Article
- Understanding the barriers and facilitators related to never treatment during mass drug administration among mobile and migrant populations in Mali: a qualitative exploratory study.BMJ global health · 2024Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well understood that the success or failure of a mass drug administration campaign critically depends on the level of coverage achieved. To that end coverage levels are often closely scrutinised during campaigns and the response to underperforming campaigns is to attempt to improve coverage. Modelling work has indicated, however, that the quality of the coverage achieved may also have a significant impact on the outcome. If the coverage achieved is likely to miss similar people every round then this can have a serious detrimental effect on the campaign outcome. We begin by reviewing the current modelling descriptions of this effect and introduce a new modelling framework that can be used to simulate a given level of systematic non-adherence. We formalise the likelihood that people may miss several rounds of treatment using the correlation in the attendance of different rounds. Using two very simplified models of the infection of helminths and non-helminths, respectively, we demonstrate that the modelling description used and the correlation included between treatment rounds can have a profound effect on the time to elimination of disease in a population. It is therefore clear that more detailed coverage data is required to accurately predict the time to disease elimination. We review published coverage data in which individuals are asked how many previous rounds they have attended, and show how this information may be used to assess the level of systematic non-adherence. We note that while the coverages in the data found range from 40.5% to 95.5%, still the correlations found lie in a fairly narrow range (between 0.2806 and 0.5351). This indicates that the level of systematic non-adherence may be similar even in data from different years, countries, diseases and administered drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.